SSR128129E free acid NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-22 |
Product Details
| Product Name: SSR128129E free acid | CAS No.: 848463-13-8 |
| Supply Ability: 10g | Release date: 2025/07/22 |
Product Introduction
Bioactivity
| Name | SSR128129E free acid |
| Description | SSR128129E (free acid) is an orally available, allosteric inhibitor of FGFR, with an IC50 of 1.9 μM for FGFR1. |
| In vitro | FGF2-induced EC proliferation(IC50 : 31±1.6 nM) inhibited by SSR128129E, migration with an IC50 of 15.2±4.5 nM, and lamellipodia formation in a dose dependent manner. SSR128129E inhibits responses mediated by FGFR1-4. SSR128129E blocks EC migration in response to FGF1, a ligand of FGFR1 and FGFR4, and capillary tube formation in response to FGF19, a ligand of FGFR4. Proliferation and migration of the murine pancreatic Panc02 tumor cell line in response to FGF7 are also blocked by SSR128129E, showing that SSR128129E inhibits FGFR subtypes of other species as well. |
| In vivo | Oral delivery of SSR128129E (30 mg/kg/day, from day 3) inhibits the growth of orthotopic Panc02 tumors by 44% and delays the growth of Lewis lung carcinoma. Administering SSR128129E orally (30 mg/kg/day, from day 5) reduces tumor size and weight by 53% and 40%, respectively. SSR128129E also inhibits the growth of subcutaneous CT26 colon tumors by 34% and the multidrug-resistant MCF7/ADR breast cancer xenograft model by 40%. Additionally, the compound reduces tumor invasiveness and metastasis of Panc02 tumor cells to peritoneal lymph nodes. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | SSR-128129E free acid | SSR128129E free acid | FGFR1 |
| Inhibitors Related | Amlexanox | Nintedanib | Ferulic Acid | Ponatinib | Nintedanib esylate | Pemigatinib | Formononetin | Lenvatinib mesylate | Erdafitinib | Lenvatinib | Masitinib | Pazopanib |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $55.00/5mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-20 | |
| $0.00/1kg |
VIP6Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-09-14 | |
| $0.00/1kg |
VIP1Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2025-04-17 | |
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY